US Stock MarketDetailed Quotes

ADAP Adaptimmune Therapeutics

Watchlist
  • 0.588
  • -0.017-2.79%
Close Dec 23 16:00 ET
  • 0.590
  • +0.002+0.34%
Post 20:01 ET
150.46MMarket Cap-3.52P/E (TTM)

Adaptimmune Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities
-20.58%-54.45M
208.31%47.4M
14.30%-31.95M
0.63%-140.88M
-818.71%-14.68M
6.23%-45.16M
-6.09%-43.76M
31.47%-37.28M
-1,421.36%-141.77M
-98.48%2.04M
Net income from continuing operations
61.37%-17.62M
425.03%69.52M
-4,781.76%-48.5M
31.18%-113.87M
-63.82%-47.92M
-10.09%-45.6M
51.96%-21.39M
102.06%1.04M
-4.66%-165.46M
24.73%-29.25M
Operating gains losses
933.13%3.43M
-206.99%-571K
-45.83%305K
108.12%198K
-911.11%-511K
113.87%332K
-236.76%-186K
330.74%563K
-551.48%-2.44M
-91.63%63K
Depreciation and amortization
-2.56%2.82M
22.85%2.74M
53.39%2.83M
61.98%9.84M
99.79%2.87M
93.96%2.89M
43.81%2.23M
15.67%1.85M
-7.49%6.08M
-35.68%1.44M
Other non cash items
65.13%-106K
100.10%21K
-114.18%-19K
-2,781.62%-21.88M
-268.63%-86K
-268.89%-304K
-6,024.93%-21.63M
-39.09%134K
-30.43%816K
104.78%51K
Change In working capital
-869.73%-45.53M
-364.79%-27.35M
124.29%10.36M
-1,529.78%-24.95M
11.17%28.28M
54.01%-4.7M
-31.77%-5.89M
-246.97%-42.65M
-101.14%-1.53M
-84.57%25.44M
-Change in receivables
-473.21%-15.36M
401.87%5.17M
324.11%15.62M
86.84%-1.29M
-102.92%-582K
61.05%-2.68M
85.90%-1.71M
134.23%3.68M
49.31%-9.81M
60.35%19.97M
-Change in payables and accrued expense
-84.04%161K
198.19%8.66M
-36,528.57%-7.65M
-306.15%-9.09M
88.00%-1.3M
-56.17%1.01M
-173.92%-8.82M
-97.82%21K
4.78%4.41M
-350.05%-10.79M
-Change in other current liabilities
--1.03M
----
----
----
----
--0
----
----
----
----
-Change in other working capital
-844.41%-28.56M
-995.61%-41.64M
105.15%2.39M
-476.20%-14.57M
85.43%30.15M
46.29%-3.02M
209.11%4.65M
-1,756.35%-46.35M
-97.41%3.87M
-89.02%16.26M
Cash from discontinued investing activities
Operating cash flow
-20.58%-54.45M
208.31%47.4M
14.30%-31.95M
0.63%-140.88M
-818.71%-14.68M
6.23%-45.16M
-6.09%-43.76M
31.47%-37.28M
-1,421.36%-141.77M
-98.48%2.04M
Investing cash flow
Cash flow from continuing investing activities
-215.20%-66.02M
-127.58%-743K
-100.74%-358K
98.05%176.54M
225.49%68.2M
98.63%57.31M
-93.89%2.69M
1,112.38%48.34M
17.59%89.14M
173.54%20.95M
Net PPE purchase and sale
50.52%-143K
65.30%-422K
95.66%-102K
84.13%-4.68M
75.78%-827K
97.11%-289K
86.43%-1.22M
66.98%-2.35M
-244.02%-29.5M
14.97%-3.42M
Net intangibles purchase and sale
---292K
-1,176.92%-332K
-47.98%-256K
18.44%-199K
--0
--0
---26K
---173K
-17.87%-244K
50.00%-13K
Net business purchase and sale
--0
----
----
--45.26M
--0
--0
----
----
--0
--0
Net investment purchase and sale
-214.82%-65.7M
--0
--0
13.59%135.03M
182.25%68.81M
46.38%57.22M
-178.89%-41.87M
2,074.56%50.86M
40.55%118.88M
199.72%24.38M
Net other investing changes
-68.62%118K
----
----
--1.12M
--211K
--376K
----
----
----
----
Cash from discontinued investing activities
Investing cash flow
-215.20%-66.02M
-127.58%-743K
-100.74%-358K
98.05%176.54M
225.49%68.2M
98.63%57.31M
-93.89%2.69M
1,112.38%48.34M
17.59%89.14M
173.54%20.95M
Financing cash flow
Cash flow from continuing financing activities
4,094.80%25M
174,985.71%24.51M
14,815.82%29.24M
-93.16%880K
-94.73%74K
-58.95%596K
-99.86%14K
460.00%196K
291.33%12.87M
2,598.08%1.4M
Net issuance payments of debt
--25M
----
----
----
----
--0
----
----
----
----
Net common stock issuance
--0
--10K
15,411.17%29.16M
-95.13%624K
-99.93%1K
-69.92%435K
--0
--188K
406.80%12.82M
--1.4M
Proceeds from stock option exercised by employees
-99.38%1K
-85.71%2K
825.00%74K
412.00%256K
812.50%73K
2,583.33%161K
1,300.00%14K
-77.14%8K
-93.41%50K
-84.62%8K
Cash from discontinued financing activities
Financing cash flow
4,094.80%25M
174,985.71%24.51M
14,815.82%29.24M
-93.16%880K
-94.73%74K
-58.95%596K
-99.86%14K
460.00%196K
291.33%12.87M
2,598.08%1.4M
Net cash flow
Beginning cash position
167.68%214.68M
18.18%143.53M
34.14%147.02M
-27.73%109.6M
15.31%93.07M
-19.42%80.2M
33.08%121.44M
-27.73%109.6M
146.68%151.67M
80.83%80.71M
Current changes in cash
-849.18%-95.47M
273.35%71.17M
-127.31%-3.07M
191.88%36.54M
119.68%53.6M
171.37%12.74M
-419.86%-41.05M
119.03%11.25M
-144.27%-39.77M
-76.87%24.4M
Effect of exchange rate changes
65.89%214K
89.47%-20K
-170.75%-416K
138.15%877K
-92.21%350K
113.51%129K
95.84%-190K
146.30%588K
-729.86%-2.3M
191.31%4.49M
End cash Position
28.31%119.42M
167.68%214.68M
18.18%143.53M
34.14%147.02M
34.14%147.02M
15.31%93.07M
-19.42%80.2M
33.08%121.44M
-27.73%109.6M
-27.73%109.6M
Free cash flow
-20.77%-54.89M
203.65%46.65M
18.83%-32.31M
15.01%-145.76M
-1,018.54%-15.5M
22.17%-45.45M
10.37%-45M
35.29%-39.81M
-8,904.36%-171.51M
-101.07%-1.39M
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities -20.58%-54.45M208.31%47.4M14.30%-31.95M0.63%-140.88M-818.71%-14.68M6.23%-45.16M-6.09%-43.76M31.47%-37.28M-1,421.36%-141.77M-98.48%2.04M
Net income from continuing operations 61.37%-17.62M425.03%69.52M-4,781.76%-48.5M31.18%-113.87M-63.82%-47.92M-10.09%-45.6M51.96%-21.39M102.06%1.04M-4.66%-165.46M24.73%-29.25M
Operating gains losses 933.13%3.43M-206.99%-571K-45.83%305K108.12%198K-911.11%-511K113.87%332K-236.76%-186K330.74%563K-551.48%-2.44M-91.63%63K
Depreciation and amortization -2.56%2.82M22.85%2.74M53.39%2.83M61.98%9.84M99.79%2.87M93.96%2.89M43.81%2.23M15.67%1.85M-7.49%6.08M-35.68%1.44M
Other non cash items 65.13%-106K100.10%21K-114.18%-19K-2,781.62%-21.88M-268.63%-86K-268.89%-304K-6,024.93%-21.63M-39.09%134K-30.43%816K104.78%51K
Change In working capital -869.73%-45.53M-364.79%-27.35M124.29%10.36M-1,529.78%-24.95M11.17%28.28M54.01%-4.7M-31.77%-5.89M-246.97%-42.65M-101.14%-1.53M-84.57%25.44M
-Change in receivables -473.21%-15.36M401.87%5.17M324.11%15.62M86.84%-1.29M-102.92%-582K61.05%-2.68M85.90%-1.71M134.23%3.68M49.31%-9.81M60.35%19.97M
-Change in payables and accrued expense -84.04%161K198.19%8.66M-36,528.57%-7.65M-306.15%-9.09M88.00%-1.3M-56.17%1.01M-173.92%-8.82M-97.82%21K4.78%4.41M-350.05%-10.79M
-Change in other current liabilities --1.03M------------------0----------------
-Change in other working capital -844.41%-28.56M-995.61%-41.64M105.15%2.39M-476.20%-14.57M85.43%30.15M46.29%-3.02M209.11%4.65M-1,756.35%-46.35M-97.41%3.87M-89.02%16.26M
Cash from discontinued investing activities
Operating cash flow -20.58%-54.45M208.31%47.4M14.30%-31.95M0.63%-140.88M-818.71%-14.68M6.23%-45.16M-6.09%-43.76M31.47%-37.28M-1,421.36%-141.77M-98.48%2.04M
Investing cash flow
Cash flow from continuing investing activities -215.20%-66.02M-127.58%-743K-100.74%-358K98.05%176.54M225.49%68.2M98.63%57.31M-93.89%2.69M1,112.38%48.34M17.59%89.14M173.54%20.95M
Net PPE purchase and sale 50.52%-143K65.30%-422K95.66%-102K84.13%-4.68M75.78%-827K97.11%-289K86.43%-1.22M66.98%-2.35M-244.02%-29.5M14.97%-3.42M
Net intangibles purchase and sale ---292K-1,176.92%-332K-47.98%-256K18.44%-199K--0--0---26K---173K-17.87%-244K50.00%-13K
Net business purchase and sale --0----------45.26M--0--0----------0--0
Net investment purchase and sale -214.82%-65.7M--0--013.59%135.03M182.25%68.81M46.38%57.22M-178.89%-41.87M2,074.56%50.86M40.55%118.88M199.72%24.38M
Net other investing changes -68.62%118K----------1.12M--211K--376K----------------
Cash from discontinued investing activities
Investing cash flow -215.20%-66.02M-127.58%-743K-100.74%-358K98.05%176.54M225.49%68.2M98.63%57.31M-93.89%2.69M1,112.38%48.34M17.59%89.14M173.54%20.95M
Financing cash flow
Cash flow from continuing financing activities 4,094.80%25M174,985.71%24.51M14,815.82%29.24M-93.16%880K-94.73%74K-58.95%596K-99.86%14K460.00%196K291.33%12.87M2,598.08%1.4M
Net issuance payments of debt --25M------------------0----------------
Net common stock issuance --0--10K15,411.17%29.16M-95.13%624K-99.93%1K-69.92%435K--0--188K406.80%12.82M--1.4M
Proceeds from stock option exercised by employees -99.38%1K-85.71%2K825.00%74K412.00%256K812.50%73K2,583.33%161K1,300.00%14K-77.14%8K-93.41%50K-84.62%8K
Cash from discontinued financing activities
Financing cash flow 4,094.80%25M174,985.71%24.51M14,815.82%29.24M-93.16%880K-94.73%74K-58.95%596K-99.86%14K460.00%196K291.33%12.87M2,598.08%1.4M
Net cash flow
Beginning cash position 167.68%214.68M18.18%143.53M34.14%147.02M-27.73%109.6M15.31%93.07M-19.42%80.2M33.08%121.44M-27.73%109.6M146.68%151.67M80.83%80.71M
Current changes in cash -849.18%-95.47M273.35%71.17M-127.31%-3.07M191.88%36.54M119.68%53.6M171.37%12.74M-419.86%-41.05M119.03%11.25M-144.27%-39.77M-76.87%24.4M
Effect of exchange rate changes 65.89%214K89.47%-20K-170.75%-416K138.15%877K-92.21%350K113.51%129K95.84%-190K146.30%588K-729.86%-2.3M191.31%4.49M
End cash Position 28.31%119.42M167.68%214.68M18.18%143.53M34.14%147.02M34.14%147.02M15.31%93.07M-19.42%80.2M33.08%121.44M-27.73%109.6M-27.73%109.6M
Free cash flow -20.77%-54.89M203.65%46.65M18.83%-32.31M15.01%-145.76M-1,018.54%-15.5M22.17%-45.45M10.37%-45M35.29%-39.81M-8,904.36%-171.51M-101.07%-1.39M
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ------Unqualified Opinion--------Unqualified Opinion--
Heat List
US
Overall
Symbol
Price
% Chg

No Data

Investment Theme CAR-T Therapy
CAR-T Therapy
Intraday+0.88%